Immunotherapy study for ovarian cancer and other tumors
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests an immunotherapy treatment for people with advanced solid tumors, including ovarian, prostate, breast, lung cancer, and sarcoma. It is specifically for tumors that have a protein called NY-ESO-1 and a certain immune type (HLA-A*0201).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have an advanced solid tumor that has spread or cannot be removed with surgery.
- Your tumor must have the NY-ESO-1 protein (confirmed by a special test).
- You need to have a specific immune system marker called HLA-A*0201.
- You must have tried at least 2 standard treatments for your cancer (or been unable to get them).
- You should be in generally good health, able to care for yourself, and have a caregiver available.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new two-drug combination (decitabine and selinexor) given with standard chemotherapy to see if it can reverse drug resistance in ovarian cancer that has come back or worsened after treatment.
This trial tests a combination treatment for advanced ovarian cancer that hasn't been treated before. It combines chemotherapy, a personalized vaccine made from your own immune cells, and a drug called pembrolizumab to help your immune system fight the cancer.
This study tests two new experimental drugs (XmAb541 and XmAb808) designed to fight advanced ovarian cancer by activating your immune system. You'll be closely monitored to see how safe the drugs are and how your body tolerates them.
This trial tests a new drug (DC05F01) for people with ovarian cancer that has come back after platinum treatment, or for those with other advanced solid tumors that haven't responded to standard therapies. It aims to see if the drug is safe and effective.
This early-phase trial tests a lab-made immune cell treatment designed to recognize ovarian cancer and attack it. It may help people with high-risk ovarian cancer who still need effective options.
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.